SciELO - Scientific Electronic Library Online

 
vol.50 issue3Partial tear of the long digital extensor tendon in a dogEconomic analysis of the risk of replacing corn grains (Zea mays) with pearl millet grains (Pennisetum glaucum) in the diet of feedlot cattle author indexsubject indexarticles search
Home Pagealphabetic serial listing  

Services on Demand

Journal

Article

Indicators

Related links

Share


Ciência Rural

Print version ISSN 0103-8478On-line version ISSN 1678-4596

Cienc. Rural vol.50 no.3 Santa Maria  2020  Epub Apr 06, 2020

https://doi.org/10.1590/0103-8478cr20180843 

CLINIC AND SURGERY

Comparison of the protocols for obtaining platelet-rich plasma in dogs: a cellular study

Comparação entre protocolos para obtenção de plasma rico em plaquetas em cães: estudo celular

André William Masseaux Vidal Júnior1  * 
http://orcid.org/0000-0003-0434-7549

Ricardo Siqueira da Silva2 

Ana Paula Lopes Marques2 

Heloísa Justen Moreira de Souza2 

1Programa de Pós-graduação em Medicina Veterinária, Universidade Federal Rural do Rio de Janeiro (UFRRJ), 23890-000, Seropédica, RJ, Brasil.

2Departamento de Medicina e Cirurgia Veterinária, Universidade Federal Rural do Rio de Janeiro (UFRRJ), Seropédica, RJ, Brasil.


ABSTRACT:

This study aimed to evaluate two protocols (PA and PB) that are used to obtain canine platelet-rich plasma (PRP) for cellularity. Twenty healthy dogs were used. Blood samples were collected and placed in two tubes of 3.2% sodium citrate. PA used double centrifugation at 210 x g, and 370 x g and PB used double centrifugation with 140 x g and 330 x g. The PRP samples from the protocols were examined in terms of their platelet, erythrocyte, and leukocyte count in the Neubauer chamber, differential leukocyte count and platelet morphological observation in blood smears. Data (mean and standard deviation) were analyzed with the 95% probability t-test (P <0.05) using Pearson’s correlation to test the relationship between platelets and erythrocytes, platelets, and leukocytes, and the leukocyte count versus the erythrocytes. Very weak negative correlation between platelets and leukocytes (p= -0.03), weak negative correlation between platelets and erythrocytes (p= -0.3) and a strong positive correlation between leukocytes and erythrocytes (ρ = 0.75) were noted. Although, BP did not reach the desired mean of one million platelets (979300 ± 79631 cells / μL), both protocols, A and B (4.42 ± 1.61 and 3.85 ± 1.55 times more platelets than total blood, respectively) (p <0.05) were efficient in concentrating platelets. Platelet activation was present in 26.55 ± 6.72% of the PA platelets and 26.25 ± 7.03% in PB (p> 0.05). PA and PB presented low erythrocyte concentration (p> 0.05), and PA had more leukocytes (p <0.05) than PB, with higher concentrations of basophils that were segmented, and lymphocytes.

Key words: growth factors; platelet-rich plasma; cell therapy; canines

RESUMO:

Foi proposto avaliar dois protocolos (PA e PB) para obtenção de plasma rico em plaquetas (PRP) canino quanto a celularidade. Foram utilizados 20 cães sadios e coletadas amostras sanguíneas, sendo acondicionados em dois tubos de citrato de sódio a 3,2%. O PA utilizando centrifugação dupla com 210 xG e 370 xG e PB utilizando centrifugação dupla com 140 xG e 330 xG. Amostras de PRP dos protocolos foram destinadas a contagem plaquetária, eritrocitária e leucocitária em câmara de Neubauer, contagem diferencial leucocitária e observação morfológica plaquetária em esfregaços sanguíneos. Analisou-se os dados (médias e desvios padrão) pelo Teste t com 95% de probabilidade (p<0,05) utilizando-se correlação de Pearson para testar a relação entre a contagem de plaquetas e eritrócitos, plaquetas e leucócitos e leucócitos em relação aos eritrócitos. Houve correlação negativa muito fraca entre plaquetas e leucócitos (ρ= -0,03), negativa fraca entre plaquetas e eritrócitos (ρ= -0,3) e correlação positiva forte entre leucócitos e eritrócitos (ρ=0,75). Embora o PB não tenha alcançando a média de um milhão de plaquetas desejado (979300 ± 79631 células/µL), ambos os protocolos, A e B (4,42 ± 1,61 e 3,85 ± 1,55 vezes mais plaquetas que o sangue total, respectivamente) (p<0,05), foram eficientes em concentrar plaquetas. A ativação plaquetária esteve presente em 26,55 ± 6,72 % das plaquetas do PA e 26,25 ± 7,03 % nas do PB (p>0,05). PA e PB apresentaram baixa concentração eritrocitária (p>0,05) e PA apresentou mais leucócitos (p<0,05) que PB, com maiores concentrações de basófilos, segmentados e linfócitos.

Palavras-chave: fatores de crescimento; plasma rico em plaquetas; terapia celular; caninos

INTRODUCTION:

Platelet-rich plasma (PRP) is generally autologous and consists of a small volume of plasma with a high concentration of platelets, growth factors (GF), and cytokines for epithelial migration, bone and connective tissue formation (MARX, 2004; CROVETTI et al., 2004; HENDERSON et al., 2003). The PRP quality is mainly measured by the ability to concentrate platelets. The PRP should have three to five times more platelets than whole blood (WHITLOW et al., 2008). However, other studies have indicated that a concentration > 1 million platelets/μL is necessary (MARX et al., 1998; LEMOS, 2002).

Dogs can benefit from PRP, associated or not with other biomaterials, in bone grafts and bone tissue regeneration, and integration in cases of experimental fractures (YOU et al., 2007; CASATI et al., 2007). The semi-automatic PRP processing method using a conventional centrifuge in a laboratory or outpatient environment provides low-cost PRP and greater applicability in veterinary medicine (VENDRAMIN et al., 2006).

All protocols should increase the platelet count to a concentration well above that reported in whole blood, preserving the platelet structure and function. If platelets are activated by releasing the GF earlier, the therapeutic action of PRP will be impaired (LÓPEZ et al., 2012).

High leukocyte concentrations in PRP may delay tendon and joint healing processes due to an increased expression of inflammatory cytokines (McCARREL et al., 2012; SCHNABEL et al., 2007; CARMONA et al., 2007). However, in contaminated skin or bone lesions, the use of PRP with higher leukocyte concentration is beneficial (MARX & GARG, 1999; BIELECKI et al., 2007; BARBOSA et al., 2008). Red blood cells in PRP may increase gel viscosity after platelet activation (ROSSI, 2001), but pain perception may increase after use due to local irritation (HALPERN et al. 2012).

In this context, the evaluation of two protocols was proposed to obtain autologous canine PRP. These semi-automatic protocols are easy to perform in an outpatient clinic and have good quality levels (platelet concentration capacity, qualitative evaluation of platelet morphology, qualitative and quantitative leukocyte classification, and reduced contamination with red blood cells).

MATERIALS AND METHODS:

The study was approved by the committee on animal research and ethics of the Federal Rural University of Rio de Janeiro (CEUA- UFRRJ) under protocol no. 1827171016. All animal owners signed an informed consent form.

This study included twenty dogs (Canis lupus familiaris) of both sexes treated at the Veterinary Hospital of the Federal Rural University of Rio de Janeiro (UFRRJ), Brazil. All dogs were aged between 1 and 7 years, with a mean age of 4 years. All presented with no clinical changes (routine consultations or elective castration procedures) and underwent blood collection. After shaving and disinfecting the cervical region with 70% alcohol, the external jugular vein was punctured using a 22G needle and 10 mL syringe to collect 10 ml of blood. Of this, 2 ml of blood was transferred to a tube containing ethylenediamine tetraacetic acid (EDTA) anticoagulant for a complete blood count (CBC) and the remaining 8 ml was divided into two 4 ml tubes containing 3.2% sodium citrate for two PRP protocols.

An impedance hematological analyzer was used for the CBC. An immersion optical microscope with a 100x objective was used for differential leukocyte count using whole blood smear slides that were instantaneously stained (Panótico Rápido®) (JAIN, 1993). Plasma concentrations of total proteins were measured using refractometry (COLES, 1987).

The blood was centrifuged (Daiki Centrifuge 80-2B, Centribio®) at 210 x g for 10 min for protocol A (PA) (ALEIXO et al., 2011, modified). After separation of the supernatant plasma, leukocyte layer, and red blood cell fraction, the supernatant plasma was divided into two fractions using an automatic micropipette. Subsequently, 50% (the upper half) of the supernatant plasma was discarded, and the lower half and the leukocyte layer were stored in a Vacutainer tube without additives for the second centrifugation at 370 x g for 10 min. Thereafter, the supernatant plasma and a red blood cell button were visualized. The automatic micropipette was sued to discard 2/3 of the supernatant plasma, and the rest was considered PRP obtained with protocol A (Figure 1). The same procedures were repeated for protocol B (PB) (KIM et al., 2002, adapted) with different centrifugation speeds and plasma fractions. The first centrifugation was at 140 x g for 10 min, and all supernatant plasma was centrifuged a second time at 330 x g for 10 min. The automatic micropipette was used to discard 2/3 of the supernatant plasma, and the rest was considered PRP obtained with protocol B. The centrifugation strength and time of each protocol was based on protocols described by ALEIXO et al. (2011) and KIM et al. (2002) that are considered efficient in concentrating platelets.

Figure 1 Platelet concentration using different protocols (PA and PB, red and green, respectively) to obtain platelet-rich plasma compared to whole blood (blue columns) from 20 dogs. 

PRP samples obtained from each protocol were diluted and homogenized to count platelets, red blood cells, and leukocytes in a Neubauer chamber after resting in a humidified chamber for 5 min. Counts were duplicated, using the mean values obtained for each sample. PRP was diluted at 1/200 (10 μl PRP in 1990 μl Brecher liquid with 1% ammonium oxalate) to determine the number of platelets. The Neubauer chamber was filled with a capillary tube, and after 20 min, an optical microscope with a 40x objective was used for counting the central reticulum (25 central medium squares = 1 mm2 area). To determine the number of red blood cells, the PRP was diluted at 1/200 (10 μl PRP in 1990 μl 0.9% saline solution), the Neubauer chamber was filled with a capillary tube, and after 5 min an optical microscope with a 40x objective was used for counting the central reticulum (25 central medium squares). For leukocytes, the PRP was diluted at 1/20 (20 μl PRP in 380 μl Thoma Liquid), the Neubauer chamber was filled with a capillary tube, and after 5 min an optical microscope with a 40x objective was used for counting the four largest lateral squares (4 mm2 area).

The formula used to obtain the total number of cells, platelets, red blood cells, and leukocytes per μl of PRP was the number of cells counted x dilution x 10 (0.1 mm height) x area, as described by COLES (1984).

Differential leukocyte counts were performed using thin, uniform PRP smear slides that were instantaneously stained (Panótico Rápido®) and visualized under an optical microscope in immersion with a 100x objective. The count started from the middle region of the smear and extended towards the tail, zigzagging through the slide. In total, 100 leukocytes were counted, and the result was presented as a percentage (relative leukocyte count). The absolute specific leukocyte count of each PRP was determined by the relationship between the global and relative specific leukocyte counts. The smear slides were used to visualize platelet morphology, with 100 platelets being counted. Their conformation was observed through pseudopod formation when activated, with the result presented as a percentage.

The confidence level was 95%, with a maximum error of 5%, and the standard deviation of the population in the pilot test did not exceed 10 points. Results are presented as a mean, standard deviation, and minimum and maximum values. The data were analyzed using the t-test with a 95% probability (p<0.05). Pearson’s correlation was used to test the relationship between platelet and red blood cell counts, platelets and leukocytes, and leukocytes and red blood cells. Prism version 6.0 software for Windows (GraphPad Software, California, USA) and Microsoft Excel 2010 software were used for the analyses.

RESULTS AND DISCUSSION:

Table 1 presents a summary of the data of the variables (platelets, red blood cells, and leukocytes) in whole blood and in each protocol evaluated. Figure 1 shows that in both the PRP protocols the number of platelets differed (p<0.05) in relation to whole blood using a manual method for platelet concentration counting in PRP for its concomitant morphological evaluation and activation analysis.

Table 1 Mean values of the platelets, red blood cells, and leukocytes obtained by the two protocols using whole blood and plasma rich in platelets from 20 dogs. 

WHOLE BLOOD Protocol A Protocol B
------------------------------------------------------------------------PLATELETS (cells/µl)------------------------------------------------------------------
Mean 285000 1135300 979300
SD 101359 158779 79631
Minimum 118000 934000 830000
Maximum 609000 1536000 1162000
----------------------------------------------------------------RED BLOOD CELLS (cells/µl)---------------------------------------------------------------
Mean 6577000 67800 59600
SD 906480 38437 48300
Minimum 5040000 20000 10000
Maximum 8970000 148000 188000
-------------------------------------------------------------------LEUKOCYTES (cells/µl)-------------------------------------------------------------------
Mean 12360 2740 1665
SD 6080 1056 1154
Minimum 6100 1250 550
Maximum 33100 4850 4350

The protocols were selected for being simple, low-cost, and efficient at concentrating platelets (ALEIXO et al., 2011; KIM et al., 2002). However, leukocytes and red blood cells were not evaluated in previous studies.

Platelet concentration in PRP should be three to five times higher than in whole blood (WHITLOW et al., 2008). Therefore, both protocols, PA and PB (4.42 ± 1.61 and 3.85 ± 1.55 times more platelets than whole blood, respectively) were efficient in concentrating platelets but differed (P<0.05) from one another (Table 2). However, other studies considered a concentration higher than 1 million platelets/μL (MARX et al., 1998; LEMOS, 2002). According to these authors, PB would not be considered a quality test for presenting a mean platelet concentration of 979,300 ± 79,631 cells/µL (Table 1). Platelet activation did not differ (p>0.05) between protocols and was relatively low (Table 2).

Table 2 Statistical summary of the percentage of platelets, mean percentage of activated platelets, percentage of red blood cells, and percentage of leukocytes in both protocols (PA and PB) to obtain platelet-rich plasma from 20 dogs. 

----Platelets (% mean over whole blood*)---- ----Activated platelets (%)--- Red blood cells (% of whole blood) Leukocytes (% of whole blood)
Protocol A Protocol B Protocol A Protocol B Protocol A Protocol B Protocol A Protocol B
Mean ± SD 442.13 ± 161.93a 385.70 ± 155.05b 26.55 ± 6.72c 26.25 ± 7.03c 1.04 ± 0.60d 0.90 ± 0.72d 26.41 ± 16.10e 15,25 ± 11,84f
Minimum 205.25 164.53 11 13 0.30 0.15 10.27 5,13
Maximum 918.64 893.22 39 57 2.42 3.07 72.13 45,90
p-value -------------0.0003----------- 0.89 --------------0.48------------- -------------0.01--------------

Data on the same line, followed by different letters indicate a statistical difference with 95% confidence.

*Mean values found after individually correlating the value in whole blood in relation to protocols A and B for each animal.

The microscopic morphological visualization of platelets using a PRP smear is recommended to evaluate the quality of the blood component, since pseudopods are formed after activation (WEISS; WARDROP, 2010), releasing growth factors in advance (EPPLEY et al., 2004). A previous study showed no morphological changes in PRP platelets obtained by direct microscopy (ALEIXO et al., 2011). However, a study using electronic microscopy to visualize platelet morphology in PRP detected 49% of platelets with uncertain activation, 41% at rest, 9% activated, and 1% damaged (ZANDIN et al., 2012). The present study detected small cytoplasmic prolongations evidencing platelet activation in 26.55 ± 6.72% of the PA platelets, and 26.25 ± 7.03% of PB platelets, with no statistical difference between them. However, the optimal amount of inactive platelets has not been established.

Red blood cells are considered PRP sample contaminants (MARX, 2004). Both protocols were considered of good quality, as demonstrated by reduced red blood cell concentration with no difference (p>0.050) among the evaluated PRPs (Table 2).

A lower number of red blood cells was previously correlated with lower gravitational force (PEREIRA, 2012), which corroborates our data since PB showed lower gravitational force (140 x g and 330 x g) than PA (210 x g and 370 x g) and concentrated less red blood cells. According to PEREIRA (2012), lower gravitational force protocols concentrate fewer platelets, which would reduce the quality of the final product. This differs from studies with equine blood, in which higher platelet counts were associated with lower centrifugal forces (VENDRUSCOLO et al., 2012). When evaluating the number of leukocytes in the PRPs, PA showed more white blood cells, significantly differing (p<0.05) from PB (Table 2).

A study on cell proliferation in tendinous lesions using plasma rich in leukocyte platelets (L-PRP) and plasma rich in pure platelets (P-PRP) showed that both treatments induced the differentiation of progenitor tendon cells into active tenocytes. However, L-PRP induced predominantly catabolic and inflammatory changes in differentiated tenocytes, increased the expression of catabolic marker genes, matrix metalloproteinases (MMP), interleukin-1beta (IL-1β), IL-6, tumor necrosis factor-alpha (TNF-α), and prostaglandin E2 (PGE 2) production. Contrastingly, P-PRP mainly induced anabolic changes, increased the genetic expression of anabolic genes, smooth muscle actin, and type I and III collagen (ZHOU et al., 2015). Only the use of P-PRP in intra-articular injections was indicated as safe to avoid catabolism and failure in tissue recovery (MATTEO et al., 2016).

There were improvements in bone and soft tissue healing processes with the use of L-PRP (YUAN et al., 2012). The PRP with a high leukocyte concentration associated with experimental fracture of the tibia in dogs resulted in a faster and more efficient repair when compared to the control group without PRP (BARBOSA et al., 2008). Therefore, PRP obtained by protocol A would be the most appropriate in fracture cases. Some studies cite the protective effect PRP against infections due to leukocytes (MARX & GARG, 1999; BIELECKI et al., 2007). In the present study, both protocols obtained lower leukocyte concentrations than whole blood, reducing possible harmful effects of such cell types on tissue repair. Values related to specific leukocyte counts are presented in table 3.

Table 3 Mean values of the absolute specific leukocyte count using the two protocols to obtain platelet-rich plasma from 20 dogs. 

----------------------------------------------------------SPECIFIC LEUKOCYTE COUNT (cells/µL)----------------------------------------------------
Protocol A Protocol B
---------------------------------------------------------Basophil-------------------------------------------------------
Mean ± SD 8.15 ± 15.04a 0 ± 0b
Minimum 0 0
Maximum 45 0
p-value -----------------------------------------------------------------0.02-----------------------------------------------------
--------------------------------------------------------------------------------Eosinophil-------------------------------------------------------------------------
Mean ± SD 19.12 ± 42.74a 18,65 ± 42,66a
Minimum 0 0
Maximum 176 168
p-value -----------------------------------------------------------------0.97-----------------------------------------------------
-------------------------------------------------------------------------------Banded neutrophil----------------------------------------------------------------
Mean ± SD 79.45 ± 38.79a 64,15 ± 69,15a
Minimum 42 5,5
Maximum 178 300
p-value -------------------------------------------------------------0.39---------------------------------------------------------
-----------------------------------------------------------------------------Segmented neutrophil--------------------------------------------------------------
Mean ± SD 410.25 ± 143.44a 244,25 ± 162,83b
Minimum 196 83
Maximum 780 713
p-value -------------------------------------------------------------0.001------------------------------------------------------
---------------------------------------------------------------------------------Lymphocyte--------------------------------------------------------------------
Mean ± SD 2214.72 ± 922.92a 1340,2 ± 949,58b
Minimum 988 451
Maximum 4074 3785
p-value ---------------------------------------------------------------0.005-----------------------------------------------------
-----------------------------------------------------------------------------------Monocyte----------------------------------------------------------------------
Mean ± SD 2.22 ± 9.95a 0 ± 0a
Minimum 0 0
Maximum 45 0
p-value -----------------------------------------------------------------0.32-----------------------------------------------------

Data on the same line, followed by different letters indicate a statistical difference with 95% confidence.

Basophils have a primary function of releasing histamine in response to allergens. Histamine increases blood flow, resulting in increased inflammation, and also stimulates neutrophils and eosinophils to leave the bloodstream to destroy antigens, with neutrophils being the first to activate cellular defense. Under basophilic signaling, neutrophils respond immediately by releasing enzymes that act by suppressing various bacteria and antigens as well as cytokines and GFs that help regeneration. Without basophils, neutrophils respond to damaged tissue or invasive bacterial protein signs (WEISS & WARDROP, 2010). PRP with a high concentration of basophils, such as that from PA, should be avoided in a tissue in which a reduced inflammatory response is desired.

A large number of neutrophils in PRP release MMPs that can lead to increased muscle damage after injury. The concentration of neutrophils in PRP has been shown to correlate positively with the expression of catabolic MMP-3 and MMP-13 in equine tendon explants, supporting the correlation between increased concentration not only of platelets, but also of leukocytes, and elevated levels of some inflammatory cytokines. This suggested a loss and possible adverse effect of white blood cells on the healing of particular tissues (SCHNABEL et al., 2007). Considering the catabolic effect of MMP, PRPs rich in neutrophils should be avoided in tendinous lesions and osteoarticular infiltrations. However, they are highly functional in bone lesions due to their antimicrobial and bone regeneration properties (BARBOSA et al., 2008).

A previous study showed the presence of white blood cells, particularly concentrated in PRP, predominantly lymphocytes (UBEZIO et al., 2014). They showed that the total biomodulator content, such as GF, in autologous plasma rich in platelets is not influenced by the lymphocyte status (UBEZIO et al., 2014). A longer time in centrifugation slightly increased platelet recovery and decreased leukocyte concentrations in the upper layer. Therefore, time can be a control parameter when low levels of white blood cells, such as lymphocytes, are required in the PRP sample (PEREZ et al., 2014).

CONCLUSION:

Both protocols concentrated platelets efficiently, with no difference between platelet activations. However, only PA reached a mean concentration higher than 1 million platelets/μL.

PA resulted in PRP with a higher leukocyte concentration than PB. Both protocols concentrated more lymphocytes in relation to other leukocyte types. PA yielded PRP with higher concentrations of basophils, neutrophils, and lymphocytes than PB.

There was no difference in the red blood cell concentration obtained between the two protocols.

ACKNOWLEDGEMENTS

This study was financed in part by Coordenação de Aperfeiçoamento de Pessoal de Nível Superior-Brasil (CAPES) - Finance code 001.

REFERENCES

ALEIXO, G. A. S. et al. Comparação entre dois protocolos para obtenção de plasma rico em plaquetas, em cães. Arquivo Brasileiro de Medicina Veterinaria e Zootecnia, v.63, n.3, p.567-573, 2011. Available from: <Available from: http://www.scielo.br/scielo.php?pid=S0102-09352011000300005&script=sci_abstract&tlng=pt >. Accessed: Apr. 16, 2017. [ Links ]

BARBOSA, A. L. T. et al. Plasma rico em plaquetas para reparação de falhas ósseas em cães. Ciência Rural, v.38, n.5, p.1335-1340, 2008. Available from: <Available from: http://www.scielo.br/scielo.php?pid=S0103-84782008000500021&script=sci_abstract&tlng=pt >. Accessed: Mar. 16, 2017. [ Links ]

BIELECKI, T. M. et al. Antibacterial effect of autologous platelet gel enriched with growth factors and other active substances: an in vitro study. Journal of Bone and Joint Surgery, v.89, p.417-420, 2007. Available from: <Available from: https://www.ncbi.nlm.nih.gov/pubmed/17356164 >. Accessed: Apr. 24, 2017. [ Links ]

CARMONA, J. U. et al. Autologous platelet concentrates as a treatment of horses with osteoarthritis: a preliminary pilot clinical study. Journal of Equine Veterinary Science, v.27, n.4, p.167-170, 2007. Available from: <Available from: https://www.sciencedirect.com/science/article/abs/pii/S0737080607000846 >. Accessed: Feb. 19, 2017. [ Links ]

CASATI, M. Z. et al. Platelet-rich plasma does not improve bone regeneration around peri-implant bone defects--a pilot study in dogs. International Journal of Oral and Maxillofacial Surgery, v.36, n.2, p.132-136, 2007. Available from: <Available from: https://www.ncbi.nlm.nih.gov/pubmed/16890407 >. Accessed: Mar. 26, 2017. [ Links ]

COLES, E. H. Veterinary Clinical Pathology, 4 ed. Philadelphia: Lea & Febiger, 1987, 421p. [ Links ]

CROVETTI, G. et al. Platelet gel for healing cutaneous chronic wounds. Transfusion and Apheresis Science, v.30, n.2, p.145-151, 2004. Available from: <Available from: http://prp.net.br/adm/pdf/Crovetti%202004%20Platelet%20Gel%20for%20chronic%20wounds.pdf >. Accessed: Apr. 14, 2017. [ Links ]

EPPLEY, B.L. et al. Platelet quantification and growth factor analysis from platelet-rich plasma: implications for wound healing. Plastic Reconstructive Surgery, v.114, p.1502-1508, 2004. Available from: <Available from: https://www.ncbi.nlm.nih.gov/pubmed/15509939 >. Accessed: Apr. 14, 2017. [ Links ]

HALPERN, B. C. et al. The role of platelet-rich plasma in inducing musculoskeletal tissue healing. HSS Journal, v.8, n.2, p.137-145, 2012. Available from: <Available from: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3715623/ >. Accessed: Apr. 14, 2017. [ Links ]

HENDERSON, J. L. et al. The effects of autologous platelet gel on wound healing. Ear Nose Throat Journal, v.82, n.8, p.598-602, 2003. Available from: <Available from: https://www.ncbi.nlm.nih.gov/pubmed/14503096 >. Accessed: Apr. 14, 2017. [ Links ]

JAIN, N. C. Veterinary Hematology. Philadelphia: Lea & Febger, 1993. 417 p. [ Links ]

KIM, S. G. et al. A comparative study of osseointegration of avana implants in a demineralized freeze-dried boné alone or with platelet-rich plasma. Journal of Oral and Maxillofacial Surgery, v.60, p.1018-1025, 2002. Available from: <Available from: https://www.ncbi.nlm.nih.gov/pubmed/12215987 >. Accessed: Apr. 14, 2017. [ Links ]

LEMOS, J. J. Utilização de PRP em enxertos ósseos - Proposta de um protocolo de obtenção simplificado. 2002. Online. Disponível em: <Disponível em: http://www.dentaria.com/artigos/ver/?art=58 >.Accessed: Dec. 08, 2016. [ Links ]

LÓPEZ, C. et al. Evaluación de un método de doble centrifugación en tubo para concentrar plaquetas bovinas: estudio celular. Archivos de medicina veterinaria, v.44, p.109-115, 2012. Available from: <Available from: https://scielo.conicyt.cl/scielo.php?script=sci_arttext&pid=S0301-732X2012000200003 >. Accessed: Dec. 08, 2016. [ Links ]

MARX, R. E. et al. Platelet-rich plasma: growth factor enhancement for bone grafts. Oral Surgery Oral Medicine Oral Pathology Oral Radiology and Endodontics, v.85, n.6, p.638-646, 1998. Available from: <Available from: https://www.ncbi.nlm.nih.gov/pubmed/9638695 >. Accessed: Jan. 19, 2017. [ Links ]

MARX, R. E.; GARG, A. K. Bone graft physiology with use of platelet-rich plasma and hiperbaric oxygen. In.: The sinus bone graft. Colorado: Quintessense, p.183-189, 1999. [ Links ]

MARX, R. E. Platelet-rich plasm: evidence to support its use. Journal of Oral and Maxillofacial Surgery, v.62, n.4, p.489-496, 2004. Available from: <Available from: http://www.drkoprp.com/pdfs/prp/PRPbyDr.Marx.pdf >. Accessed: Apr. 03, 2017. [ Links ]

MCCARREL, T. et al. Optimization of leukocyte concentration in platelet-rich plasma for the treatment of tendinopathy. The Journal of Bone and Joint Surgery, v.94, n.143, p.141-148, 2012. Available from: <Available from: https://www.ncbi.nlm.nih.gov/pubmed/23032594 >. Accessed: Apr. 14, 2017. [ Links ]

PEREIRA, R. C. F. Avaliação de sete protocolos de obtenção de plasma rico em plaquetas (PRP). 2012. Dissertação de Mestrado em Medicina Veterinária. Santa Maria, RS, Brasil:Universidade Federal de Santa Maria- Centro de Ciências Rurais, 2012. Available from: <Available from: http://www.scielo.br/scielo.php?pid=S0103-84782013000600028&script=sci_abstract&tlng=pt >. Accessed: Apr. 14, 2017. [ Links ]

PEREZ, A. G. et al. Relevant aspects of centrifugation step in the preparation of platelet-rich plasma. International Scholarly Research Notices: Hematology, v.2014, p.1-8, 2014. Available from: <Available from: https://www.hindawi.com/journals/isrn/2014/176060/ >. Accessed: Jan. 10, 2017. [ Links ]

SCHNABEL, L. V. et al. Platelet rich plasma (PRP) enhances anabolic gene expression patterns in flexor digitorum superficialis tendons. Journal of Orthopedic Research, v.25, p.230-240, 2007. Available from: <Available from: https://www.ncbi.nlm.nih.gov/pubmed/17106885 >. Accessed: Apr. 14, 2017. [ Links ]

UBEZIO, G. et al. Bio-modulators in platelet-rich plasma: a comparison of the amounts in products from healthy donors and patients produced with three different techniques. Blood Transfusion. v.12, Suppl.1, p.214-220, 2014. Available from: <Available from: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3934217/ >. Accessed: Jun. 27, 2016. [ Links ]

VENDRAMIN, F. S. et al. PRP e FC: técnica de obtenção e utilização em cirurgia plástica. Revista do Colégio Brasileiro de Cirurgiões, v.33, n.1, p.24-28, 2006. Available from: <Available from: http://www.scielo.br/scielo.php?script=sci_arttext&pid=S0100-69912006000100007 >. Accessed: Apr. 14, 2017. [ Links ]

VENDRUSCOLO, C. P. et al. Plasma rico em plaquetas: uma nova perspectiva terapêutica para medicina equina. Veterinária e Zootecnia, v.19, n.1, p.33-43, 2012. v.19 ,n.1,from: <1,from: https://www.researchgate.net/publication/258262654_PLASMA_RICO_EM_PLAQUETAS_UMA_NOVA_PERSPECTIVA_TERAPEUTICA_PARA_MEDICINA_EQUINA >. Accessed: Apr. 14, 2017. [ Links ]

WEISS, D. J., WARDROP, K. J. Schalm’s veterinary hematology. 6 ed. Iowa: Blackwell Publishing. p.1232, 2010. [ Links ]

WHITLOW, J. et al. Barriers to the acceptance and use of autologous platelet gel. Perfusion, v.23, p.283-289, 2008. Available from: <Available from: https://www.ncbi.nlm.nih.gov/pubmed/19346267 >. Accessed: Apr. 14, 2017. [ Links ]

YOU, T. M. et al. The effect of platelet-rich plasma on bone healing around implants placed in bone defects treated with Bio-Oss: a pilot study in the dog tibia. Oral Surgery, Oral Medicine, Oral Pathology, Oral Radiology, and Endodontics, v.103, n.4, p.8-12, 2004. Available from: <Available from: https://www.google.com/search?q=The+effect+of+platelet-rich+plasma+on+bone+healing+around+implants+placed+in+bone+defects+treated+with+Bio-Oss%3A+a+pilot+study+in+the+dog+tibia&oq=The+effect+of+platelet-rich+plasma+on+bone+healing+around+implants+placed+in+bone+defects+treated+with+Bio-Oss%3A+a+pilot+study+in+the+dog+tibia&aqs=chrome..69i57.2573j0j4&sourceid=chrome&ie=UTF-8 >. Accessed: May, 12, 2017. [ Links ]

YUAN, T. et al. Applications of leukocyte-and platelet-rich plasma (L-PRP) in trauma surgery. Current Pharmaceutical Biotechnology, v.13, n.7, p.1173-1184, 2012. Available from: <Available from: https://www.researchgate.net/publication/51478027_Applications_of_Leukocyte-_and_Platelet-Rich_Plasma_L-PRP_in_Trauma_Surgery >. Accessed: Apr. 14, 2017. [ Links ]

ZANDIM, B. M. et al. Platelet activation : Ultrastructure and morphometry in platelet-rich plasma of horses. Pesquisa Veterinária Brasileira, v.32, n.1, p.83-92, 2012. Available from: <Available from: http://www.scielo.br/scielo.php?script=sci_arttext&pid=S0100-736X2012000100014 >. Accessed: Mar. 07, 2017. [ Links ]

ZHOU, Y. et al. The differential effects of leukocyte-containing and pure platelet-rich plasma (PRP) on tendon stem/progenitor cells - implications of PRP application for the clinical treatment of tendon injuries. Stem Cell Research & Therapy, v.6, n.1, p.173, 2015. Available from: <Available from: https://www.google.com/search?q=The+differential+effects+of+leukocyte-containing+and+pure+platelet-rich+plasma+(PRP)+on+tendon+stem%2Fprogenitor+cells+-+implications+of+PRP+application+for+the+clinical+treatment+of+tendon+injuries.&oq=The+differential+effects+of+leukocyte-containing+and+pure+platelet-rich+plasma+(PRP)+on+tendon+stem%2Fprogenitor+cells+-+implications+of+PRP+application+for+the+clinical+treatment+of+tendon+injuries.&aqs=chrome..69i57.2575j0j4&sourceid=chrome&ie=UTF-8 >. Accessed: Jun. 23, 2016. [ Links ]

CR-2018-0843.R3

BIOETHICS AND BIOSSECURITY COMMITTEE APPROVAL

This study was approved by the Committee on Animal Research and Ethics of the Federal Rural University of Rio de Janeiro (CEUA-IV, UFRRJ), under protocol no. 1827171016. All animal owners signed a free and informed consent form.

Received: October 11, 2018; Accepted: December 20, 2019; Revised: February 14, 2020

E-mail: andremasseaux@gmail.com. *Corresponding author.

DECLARATION OF CONFLICT OF INTERESTS

The authors declare no conflict of interest. The founding sponsors had no role in the design of the study; in the collection, analyses, or interpretation of data; in the writing of the manuscript; and in the decision to publish the results.

AUTHORS’ CONTRIBUTIONS

The authors contributed equally to the manuscript.

Creative Commons License This is an open-access article distributed under the terms of the Creative Commons Attribution License